Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

243 - Emodin Sensitizes Ovarian Cancer Cells to Carboplatin through Suppression of Mitochondrial Respiration


24 Nov 2018


Poster display - Cocktail


Tumour Site

Ovarian Cancer


Yuhong Ge


Annals of Oncology (2018) 29 (suppl_9): ix23-ix27. 10.1093/annonc/mdy430


Y. Ge, Y. Chen, W. Wang, D. Wu, F. Cao, X. Zhou, J. Gao, Z. Cao, X. Zheng, W. Li, J. Li

Author affiliations

  • Guiyang University Of Chinese Medicine, Basic Medical College, Guiyang University of Chinese Medicine, 550025 - Guiyang/CN


Abstract 243


Ovarian cancer is the most lethal gynecologic malignancy. So far, the clinical therapeutic effect is quite poor under the condition of platinum-based chemotherapy, and enhancing the therapeutic effect of platinum-based drugs (carboplatin, etc) could be important to optimizing treatment.


In light of the enhanced DNA repair function which offsets the effect of carboplatin to increase the damage of DNA, we examined and discussed emodin, which is the chemical component of rhubarb that could inhibit DNA repair to overcome carboplatin resistance, increasing the sensitivity of cisplatin treatment.


Compared with simple carboplatin treatment, the combination of emodin and carboplatin can significantly reduce the survival rate of SKOV3 in ovarian cancer cells, presenting a dose and time dependence. The Combination Index of the Combination of emodin and carboplatin was calculated (CI < 1), suggesting that they had significant synergistic antitumor activity. And our study found that emodin had an increase in the signals of γ-H2AX, inhibiting the expression of RAD51 in ovarian cancer cells. The further study showed that emodin increased the NADH content, inhibiting oxidative phosphorylation.


This study suggests that emodin could inhibit oxidative phosphorylation, suppress DNA damage repair, and increase the DNA damage of ovarian cancer cells induced by carboplatin. Emodin could be a potential sensitizer to enhance the therapeutic efficacy of carboplatin chemotherapy.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Yuhong Ge.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.